Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

TerThera Terbium-161 isotope supply agreement expanded

Thursday, August 24, 2023 1 min read
Key Takeaway: TerThera has expanded its supply agreement for the Terbium-161 isotope, indicating a strategic move to enhance its operational capacity. This expansion is expected to support ongoing clinical trials and future projects. The agreement reflects the company's commitment to advancing its therapeutic offerings in radiopharmaceuticals.

Market Sentiment Analysis

POSITIVE FACTORS

  • Expansion of isotope supply agreement indicates growth potential.
  • Increased supply may enhance clinical trial capabilities.
  • Positive outlook for future collaborations and developments.

Full Press Release Details

• Announcements
• Price Sensitive
• August 24, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• September 5, 2022
• Updates
• March 14, 2024
• Announcements
• July 17, 2024
• Announcements
• September 18, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the Terbium-161 isotope supply agreement?

The Terbium-161 isotope supply agreement is a contract that supports TerThera's operations in radiopharmaceuticals.

Why is the expansion of the supply agreement significant?

The expansion indicates growth potential and enhances clinical trial capabilities for TerThera.

What impact does this agreement have on clinical trials?

The expanded supply is expected to support ongoing and future clinical trials for TerThera.

Who is TerThera?

TerThera is a company focused on developing radiopharmaceuticals for therapeutic applications.

Tags: RADX Viatris Investor Conferences Healthcare TerThera isotope supply clinical trials radiopharmaceuticals
Last updated: Aug 24, 2023